180 Life Sciences, operating under the name ETHZilla, has made a significant investment in Ethereum (ETH). According to PANews, the company currently holds 82,186 ETH valued at approximately $349 million, acquired at an average price of $3,806.71 per ETH. Additionally, they hold around $238 million in cash equivalents. This investment will be long-term, with ETHZilla planning to generate returns through staking and utilizing a proprietary Ethereum network strategy alongside Electric Capital. Their strategic shift aims to transform them into an institutional-grade Ethereum reserve management platform while continuing to develop their gaming and biotechnology ventures.